Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-15T19:33:30.659Z Has data issue: false hasContentIssue false

PW01-18 - Utilization and Expenditures for Lisdexamfetamine Dimesylate Compared to Other Attention-Deficit/Hyperactivity Disorder (ADHD) Medications in the Texas Medicaid Program

Published online by Cambridge University Press:  17 April 2020

K. Lawson
Affiliation:
The University of Texas, USA
M. Johnsrud
Affiliation:
Avalere Health, LLC, Austin, TX, USA
R. Sasane
Affiliation:
Shire Development Inc., Wayne, PA, USA
P. Hodgkins
Affiliation:
Shire Development Inc., Wayne, PA, USA
M.L. Crismon
Affiliation:
The University of Texas, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

To determine if utilization and expenditures differ between a newly-marketed (at time of study) ADHD medication (lisdexamfetamine dimesylate [LDX]) and existing medications.

Methods

Prescription and medical claims for Texas Medicaid patients diagnosed with ADHD newly initiated on an ADHD medication (no previous use for 180 days) during August and September 2007 were analyzed. Logistic and linear regressions were used to evaluate differences in adherence, persistence, switching, and expenditures during a 180-day post-initiation period between the LDX group and existing medications (immediate-release methylphenidate [IR-M] and amphetamines [IR-A] and extended-release methylphenidate [ER-M] and amphetamines [ER-A, excluding LDX]) with relevant demographic and preinitiation period comorbidities, utilization, and expenditure variables as covariates. Because prior authorization was required, the non-stimulant atomoxetine was excluded.

Results

The sample consisted of 1810 subjects with 69% aged 6 to 12 years; 58.0% were initiated on ER-M and 14.4% on LDX. Psychiatrists prescribed 60.5% of LDX prescriptions. A greater proportion of LDX patients had psychiatric-related comorbidities compared to the other medication groups. Logistic regression showed that compared to the LDX group, the IR-M group was more likely to discontinue therapy (OR=1.95, 95%CI=1.05-3.60, P=0.034), and the IR-A group was more likely to switch therapy (OR=2.39, 95%CI=1.22-4.69, P=0.012). ADHD medication expenditures were significantly lower for the LDX group than the ER groups (all P≤0.003). ADHD-related and total medical expenditures did not differ significantly.

Conclusions

Although used in more complex patients, LDX demonstrated advantages over IR-M on persistence, IR-A on therapy switching, and the ER groups on medication expenditures.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.